12/1
09:05 am
pmn
Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/1
07:30 am
pmn
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Medium
Report
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
12/1
07:28 am
pmn
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference [Canadian Business Journal (Canada)]
Medium
Report
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference [Canadian Business Journal (Canada)]
12/1
07:00 am
pmn
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Medium
Report
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
11/29
03:35 am
pmn
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre
Medium
Report
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre
11/24
08:00 am
pmn
ProMIS Neurosciences Announces Reverse Stock Split
Medium
Report
ProMIS Neurosciences Announces Reverse Stock Split
11/21
08:05 am
pmn
Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
11/18
09:34 am
pmn
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $6.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $6.00 to $5.00. They now have a "buy" rating on the stock.
11/15
07:05 pm
pmn
Can ProMIS Neurosciences (NASDAQ:PMN) Afford To Invest In Growth? [Yahoo! Finance]
High
Report
Can ProMIS Neurosciences (NASDAQ:PMN) Afford To Invest In Growth? [Yahoo! Finance]
11/12
07:28 am
pmn
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights [Canadian Business Journal (Canada)]
Low
Report
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights [Canadian Business Journal (Canada)]
11/12
07:00 am
pmn
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
Medium
Report
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
11/3
05:28 pm
pmn
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference [Canadian Business Journal (Canada)]
Low
Report
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference [Canadian Business Journal (Canada)]
11/3
04:05 pm
pmn
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Low
Report
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
10/22
07:30 am
pmn
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
Medium
Report
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
10/11
01:10 am
pmn
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre
Medium
Report
Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre